Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.33B 11.46B 10.54B 19.76B 1,358B 20.11B 137B 53.43B 662B 52.64B 51.5B 2,298B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.47B 10.65B 9.8B 18.37B 1,263B 18.7B 127B 49.68B 616B 48.94B 47.89B 2,136B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 28.4
Extreme 28.4
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Compliance Officer 64 02/07/2019
Chief Tech/Sci/R&D Officer - 01/04/2022
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
2/4/25 Issuer saleCompany 10,000 0.0094%
2/4/25 Issuer sale

Director

52,606 0.0495%
2/4/25 Issuer sale

Director

55,511 0.0522%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+112.42% 14.02B
+0.11%-3.98%+13.89%-11.26% 66.32B
+2.35%+3.89%+38.96%+205.33% 52.6B
+0.51%+37.90%+37.90%+37.90% 43.27B
-1.32%-7.38%-57.63%-57.10% 38.64B
+1.46%-3.97%+53.17%-27.51% 29.62B
+0.78%+0.03%+65.07%+81.90% 23.31B
-1.81%-9.71%+64.46%-54.90% 22.62B
-1.21%+1.12%+1.98%+170.93% 20.22B
-0.11%-0.74%+62.32%+124.27% 16.29B
Average +0.26%-2.61%+28.01%+58.20% 32.69B
Weighted average by Cap. +0.42%-2.48%+24.44%+50.15%

Financials

2023 2024
Net sales 464M 408M 379M 349M 654M 44.97B 666M 4.54B 1.77B 21.93B 1.74B 1.71B 76.1B 681M 599M 556M 512M 959M 65.93B 977M 6.65B 2.59B 32.16B 2.56B 2.5B 112B
Net income -140M -123M -114M -105M -197M -13.53B -200M -1.36B -532M -6.6B -524M -513M -22.89B -74.68M -65.68M -61.01M -56.12M -105M -7.23B -107M -730M -285M -3.53B -280M -274M -12.24B
Net Debt -481M -423M -393M -361M -678M -46.58B -690M -4.7B -1.83B -22.72B -1.81B -1.77B -78.82B -984M -866M -804M -740M -1.39B -95.3B -1.41B -9.61B -3.75B -46.48B -3.69B -3.61B -161B
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock